Chisom Kanu

Changes in patient-reported outcomes and objective assessments based on baseline symptom severity in SURMOUNT-OSA: post-hoc analyses

Chisom Kanu, Shraddha Shinde, Beverly Falcon, Josef Bednařík et autres

Abstract Study Objectives These post-hoc analyses of SURMOUNT-OSA evaluated patient-reported outcome measures (PROMs) and objective assessments, considering participants’ baseline characterization of fatigue, sleepiness, snoring, and sleep quality. Materials and Methods SURMOUNT-OSA included two 52-week randomized, placebo-controlled studies of tirzepatide (10/15 mg) in …

us (code pays fourni par la source)

Multi-stakeholder use of patient experience data (PED): current state and future opportunities for the application of PED to inform decision-making

Chisom Kanu, Jessica L. Abel, Sarah L. Knight, Nicola Williamson et autres

Patient experience data (PED) encompass information on patient’s experiences, disease impact, and treatment preferences. PED are critical inputs to the drug development process and help ensure medicines are developed with the interests of patients in mind. The authors (all members of the …

us, gb, ch, jp, fr (code pays fourni par la source)

Development of the Weight and Emotions Scale (WES)

Chisom Kanu, Miriam Kimel, Iris Goetz, Lisa M. Neff et autres

ABSTRACT Objective Obesity and overweight are associated with significant psychosocial burden. Existing patient‐reported outcome (PRO) measures only assess a subset of emotion‐related concepts that are relevant to individuals living with these conditions. The Weight and Emotions Scale (WES) was developed to enable …

us (code pays fourni par la source)

Psychometric Validation of the Eating Behavior and Appetite Questionnaire (EBAQ) for Individuals with Obesity or Overweight

Chisom Kanu, Miriam Kimel, Claudine Clucas, Iris Goetz et autres

INTRODUCTION: Obesity management medications influence eating behavior and promote substantial weight reduction in individuals with obesity or overweight. Existing patient-reported outcome measures do not adequately measure appetite and eating behavior concepts relevant to individuals with these conditions. This study presents psychometric properties …

us, gb, il (code pays fourni par la source)

Development and Content Evaluation of the Eating Behavior and Appetite Questionnaire (EBAQ) for Individuals with Obesity

Chisom Kanu, Claudine Clucas, Anne M. Skalicky, Ashley Samuelson et autres

INTRODUCTION: Obesity management medications can reduce body weight and have an impact on patients' appetite and eating behaviors. Existing patient-reported outcome (PRO) measures do not fully capture appetite and eating behavior concepts relevant to individuals living with obesity, including those receiving treatment. …

us, gb, il (code pays fourni par la source)

Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial

IRIS A. GOETZ, Chisom Kanu, Anastasia Hoover, Cecilia Jimenez‐Moreno et autres

Background: Retatrutide, an agonist of glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptors, is in development for the treatment of obesity. We interviewed participants exiting a phase 2 trial to understand the impact of retatrutide on eating behaviors, physical aspects, emotions, and …

us (code pays fourni par la source)

P017 Association Between Tirzepatide and Fatigue and Functioning Based on Baseline Characterization: SURMOUNT-OSA Trials

Terri E. Weaver, Shraddha Shinde, Chunyuan Xie, Josef Bednařík et autres

Abstract Introduction Daytime sleepiness, a common symptom of obstructive sleep apnea (OSA), can be measured via multiple patient-reported outcome questionnaires. It is hypothesized that tirzepatide may reduce daytime sleepiness, as it showed significant improvements in the apnea hypopnea index in the SURMOUNT-OSA …

us, au (code pays fourni par la source)

Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study

Chisom Kanu, Kristina Secnik Boye, Jiat Ling Poon, IRIS A. GOETZ et autres

AIMS: To determine whether adults with type 2 diabetes (T2D) treated with retatrutide report greater changes in self-reported appetite, dietary restraint, and disinhibition compared to placebo or dulaglutide and to examine associations with weight change. MATERIALS AND METHODS: These pre-specified exploratory analyses …

us, gb (code pays fourni par la source)

Author response for "Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study"

Chisom Kanu, Kristina Secnik Boye, Jiat Ling Poon, IRIS A. GOETZ et autres

Assessing participants’ experiences with the COVID-19 symptom diary in a clinical trial

T. Michelle Brown, Chisom Kanu, Magdalena Alicja Harrington

During a phase 2/3 study of twice-daily nirmatrelvir 300 mg coadministered with ritonavir 100 mg versus placebo for 5 days (NCT05011513), participants reported presence and severity of COVID-19 symptoms using a COVID-19 symptom diary in accordance with FDA guidance. Here, we aimed …

us (code pays fourni par la source)

Association between patient‐reported eating behaviours and weight change: Secondary analyses of a randomized, double‐blind trial comparing retatrutide and placebo in people with obesity or overweight

Chisom Kanu, Qiwei Wu, Jiat Ling Poon, IRIS A. GOETZ et autres

us (code pays fourni par la source)

Development of the Pediatric Weight Questionnaire (PWQ™) for Children and Adolescents with Obesity

Kristina Secnik Boye, Amy G. Clark, Chisom Kanu, Lisa M. Neff et autres

INTRODUCTION: Development of obesity management medications (OMMs) for use in children and adolescents calls for patient-reported outcome (PRO) measures to evaluate treatment efficacy. Existing weight-specific symptom and impact PROs are limited to age ≥ 11 years and may not fully capture treatment …

us (code pays fourni par la source)